Inactivation of intestinal bacteria reduces the risk of cardiovascular disease

This bacterium, named akhmann's mucoprotein, is one of the main members of human intestinal flora and was isolated and identified for the first time in 2004Previous animal experiments have shown that it has the effect of inhibiting metabolic diseases such as type 2 diabetes, and the effect of inactivation of the bacteria on reducing the risk of cardiovascular disease is even better than that of living bacteria< br / > researchers at the University of Leuven, Belgium, have carried out small-scale human trials with the mucoprotein strain for the first time, according to a press release< br / > 32 overweight or obese volunteers completed the trial, the team said in a paper published in the British journal Nature MedicineThe volunteers were divided into three groupsEach group received oral administration of live mucinophilic bacteria, pasteurized bacteria or placebo, without changing their diet and exercise habits< br / > the results showed that the increase of insulin sensitivity and the decrease of plasma total cholesterol level of the volunteers taking inactivated bacteria after 3 months indicated that they had a lower risk of cardiovascular disease and type 2 diabetesThese indicators continued to deteriorate in the placebo group< br / > in addition, the inactivated bacteria also reduced the body weight, body fat and hip circumference of the volunteers, and the level of some inflammatory markers in the liver< br / > in the experiment, the dosage of volunteers was 10 billion living bacteria or inactivated bacteria every dayAfter three months of continuous administration, there was no side effect, and the safety and tolerance were goodThe researchers say this shows that it is feasible to use the bacteria as a dietary supplement.